 SAN DIEGO, July 30, 2020 GLOBE NEWSWIRE -- Kura Oncology, Inc. Nasdaq: KURA, a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report second quarter 2020 financial results after the close of U.S. financial markets on Thursday, August 6, 2020. Kuras management will host a webcast and conference call at 4:30 p.m. ET 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 866 278-7953 for domestic callers and 323 347-3281 for international callers and entering the conference code: 1697775. A live webcast and archive of the call will be available online from the investor relations section of the company website at About Kura OncologyKura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Companys pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kuras most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial AIM-HN in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Companys pipeline is also highlighted by KO-539, a potent and selective inhibitor of the menin-KMT2AMLL protein-protein interaction currently in a Phase 12A clinical trial KOMET-001 in patients with relapsedrefractory acute myeloid leukemia. For additional information about Kura, please visit the Companys website at Pete De Spain Vice President, Investor Relations Corporate Communications 858 500-8803 Robert H. Uhl Managing Director Westwicke ICR 858 356-5932 Jason Spark Managing Director Canale Communications 619 849-6005 